Insight, China's Pharmaceutical Industry

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

BrainAurora Medical Technology Limited (HKG: 6681), China’s pioneer in neuroscience-AI integrated digital therapeutics, announced a...

Company Drug

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Fineline Cube Mar 28, 2026

UCB (EBR: UCB) announced National Medical Products Administration (NMPA) approval for Bimzelx (bimekizumab) in two...

Company Drug

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

Fineline Cube Mar 28, 2026

Enhertu (trastuzumab deruxtecan), the HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (NYSE: AZN) and Daiichi...

Company Drug

FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

Fineline Cube Mar 28, 2026

The U.S. Food and Drug Administration (FDA) this week approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel),...

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026

C-Ray Therapeutics, a Chengdu-based radiopharmaceuticals specialist, announced a master radioisotope supply agreement with SHINE Technologies,...

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026

Novo Nordisk (NYSE: NVO) announced FDA approval for Awiqli (insulin icodec), becoming the world’s first...

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) received National Medical Products Administration (NMPA)...

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Fineline Cube Mar 27, 2026

CStone Pharmaceuticals (HKG: 2616) reported 2025 financial results, with annual sales declining 33.8% YoY to...

Company Drug

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

Fineline Cube Mar 27, 2026

Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced clinical trial approval from China’s National...

Company Drug

Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Fineline Cube Mar 27, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced clinical trial approval from China’s National Medical Products...

Company Drug

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Fineline Cube Mar 27, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced that NEOK Bio, Inc., its...

Company Drug

Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile

Fineline Cube Mar 27, 2026

Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that JKN2404 inhalation suspension, a Category...

Company

Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%

Fineline Cube Mar 27, 2026

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5%...

Company Drug

Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis

Fineline Cube Mar 26, 2026

Pulmongene (Beijing) Ltd. announced that PMG1015 received Fast Track Designation (FTD) from the U.S. Food...

Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026

China’s State Council issued “Opinions on Accelerating the Establishment of a Long-Term Care Insurance System”,...

Company

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

Fineline Cube Mar 26, 2026

Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to...

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026

GlaxoSmithKline (GSK; NYSE: GSK) formed a strategic alliance with SPH Keyuan Trade, a China pharmaceutical...

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for...

Others

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

Fineline Cube Mar 26, 2026

Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR...

Company Drug

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

Fineline Cube Mar 26, 2026

Partners United Laboratories International Holdings Ltd (HKG: 3933) and Novo Nordisk (NYSE: NVO) announced positive...

Insight, China's Pharmaceutical Industry

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile

Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%

Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%

United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los

You Missed

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor